Prosecution Insights
Last updated: November 04, 2026
Application No. 18/268,030

TRIARYL BORANE CATALYSTS AND METHOD FOR SELECTIVE HYDROSILYLATION OF ESTERS AND LACTONES USING SAID CATALYSTS

Final Rejection §103§112
Filed
Jun 16, 2023
Priority
Dec 18, 2020 — HU P2000437 +1 more
Examiner
BAKSHI, PANCHAM
Art Unit
1623
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Aldexchem Kft
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allowance Rate
902 granted / 1176 resolved
+16.7% vs TC avg
Strong +30% interview lift
Without
With
+30.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
76 currently pending
Career history
1252
Total Applications
across all art units

Statute-Specific Performance

§101
1.6%
-38.4% vs TC avg
§103
30.5%
-9.5% vs TC avg
§102
20.0%
-20.0% vs TC avg
§112
30.3%
-9.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1176 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Application Claims 4-16 are pending, of which 9-16 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention, there being no allowable generic or linking claim. Claims 4-8 are under current examination. Amendment necessitated new claim rejection as set forth below. Newly submitted claim 16 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: Claim 16 is drawn to catalyst having structure different from the claims that are originally presented. Since applicants have received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 16 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03. To preserve a right to petition, the reply to this action must distinctly and specifically point out supposed errors in the restriction requirement. Otherwise, the election shall be treated as a final election without traverse. Traversal must be timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are subsequently added, applicant must indicate which of the subsequently added claims are readable upon the elected invention. Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103 or pre-AIA 35 U.S.C. 103(a) of the other invention. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), fourth paragraph: Subject to the [fifth paragraph of 35 U.S.C. 112 (pre-AIA )], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claims 6-8 are rejected under 35 U.S.C. 112(d), as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claims 6-8 are in an improper dependent form because: According to claim 4, Y PNG media_image1.png 127 1016 media_image1.png Greyscale and according to substituents, it cannot be perfluoro [1,1’-biphenyl]-2yl. Claims 6-8, dependent on claim 4, are therefore improper and broader than claim 4. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 4-8 and elected species are rejected under 35 U.S.C. 103 as being unpatentable over Hoshimoto (JACS, 2018, 140, 7292-7300; as provided by the applicant on IDS dated 03/25/2024). Determining the scope and contents of the prior art Hoshimoto discloses triarylborane compounds: PNG media_image2.png 301 391 media_image2.png Greyscale X=X’=Y=phenyl; para substituent on rings X, X’ is (i.e., R4 and R4’) H; rest of the 4 substituents on rings X, X’ are F (R1-R3, R1’-R3’, R5 and R5’) and ring Y, R6-R9=H and R10=CF3, alkyl substituted with halogen (entire article, especially page7293). Further, the cited prior art teaches compound B(2,6-Cl2C6H3) (p-HC6F4)2, i.e., compound 5 in the cited prior art. Compound 5 is closely similar to the elected species with same substitutions on rings X and X’ and halogen substitution at both positions 2 and 6 of ring Y with a difference that both halogens on ring Y of the cited prior art are Cl vs elected species one halogen is F and the other halogen is Br. The cited prior art further teaches superior catalytic activity of compound 5 in reductive alkylation of amine. Ascertaining the differences between the prior art and the claims at issue Hoshimoto discloses triarylborane compounds, such as Compound 5, closely similar to the elected species with same substitutions on rings X and X’ and halogen substitution at both positions 2 and 6 of ring Y with a difference that both halogens on ring Y of the cited prior art are Cl vs elected species one halogen is F and the other halogen is Br. Resolving the level of ordinary skill in the pertinent art With regards to the above difference, Hoshimoto discloses triarylborane compounds, such as Compound 5, closely similar to the elected species with same substitutions on rings X and X’ and halogen substitution at both positions 2 and 6 of ring Y with a difference that both halogens on ring Y of the cited prior art are Cl vs elected species one halogen is F and the other halogen is Br. The cited prior art further teaches superior catalytic activity of compound 5 in reductive alkylation of amine. Since the cited prior art teaches halogen, specifically Cl, at both 2 and 6 positions of ring Y and halogen genus contains a small number of members, it would have been prima facie obvious to a person of ordinary skill in the art with a reasonable expectation of success that Cl at position 2 and 6 may be replaced with other halogen, such as F, Br and I. Further a person of ordinary skill in the art would have been motivated to try other halogens at these positions based on prior art teaching of superior catalytic activity of the compound. Since the cited prior art teaches halogen, specifically Cl, at both 2 and 6 positions of ring Y and halogen genus contains a small number of members that, when considered in light of the totality of the circumstances, “one skilled in [the] art would... envisage each member” of the genus. In re Petering, 301 F.2d 676, 681, 133 USPQ 275, 280 (CCPA 1962). Based on the above established facts, it appears that the combination of teachings of above cited prior art read applicants’ compound. Therefore, all the claimed elements were known in the prior art and one skilled person in the art could have combined the elements as claimed by known methods with no change in their respective functions, and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Considering objective evidence present indicating obviousness or nonobviousness To establish a prima facie case of obviousness, three basic criteria must be met: (1) the prior art reference must teach or suggest all the claim limitations; (2) there must be some suggestion or motivation, either in the references themselves or in the knowledge generally available to one of ordinary skill in the art, to modify the reference or to combine reference teachings; and (3) there must be a reasonable expectation of success; and (MPEP § 2143). In this case, Hoshimoto discloses triarylborane compounds, same as in the instant claims 1 and 3 and compound 5, closely similar to the elected species with same substitutions on rings X and X’ and halogen substitution at both positions 2 and 6 of ring Y. In KSR International Vo. V. Teleflex Inc., 82 USPQ2d (U.S. 2007), the Supreme Court particularly emphasized “the need for caution in granting a patent based on a combination of elements found in the prior art,” (Id. At 1395) and discussed circumstances in which a patent might be determined to be obvious. Importantly, the Supreme Court reaffirmed principles based on its precedent that “[t]he combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” (Id. At 1395). See MPEP 2143 - Examples of Basic Requirements of a Prima Facie Case of Obviousness [R-9]. In this case at least prong (E) “Obvious to try” – choosing from a finite number of identified, predictable solutions, with a reasonable expectation of success would apply. The rationale to support a conclusion that the claim would have been obvious is that “a person of ordinary skill has good reason to pursue the known options within his or her technical grasp. If this leads to the anticipated success, it is likely that product [was] not of innovation but of ordinary skill and common sense. In that instance the fact that a combination was obvious to try might show that it was obvious under § 103.”KSR, 550 U.S. at ___, 82 USPQ2d at 1397. If any of these findings cannot be made, then this rationale cannot be used to support a conclusion that the claim would have been obvious to one of ordinary skill in the art. Further, there is a reasonable expectation of success that 2 and 6 position halogens of compound 5 of the cited prior art may be replaced with other halogen and can be made by teachings of the above cited prior art. Therefore, it would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention by taking advantage of the teaching of the above cited references and making the instantly claimed compound with a reasonable expectation of success. Modifying such parameters is prima facie obvious because an ordinary artisan would be motivated to develop an alternative compound for economic reasons or convenient purposes from a known individual compound, and to arrive at applicant’s compound with a reasonable expectation of success. Response to Arguments Applicants’ remarks and amendments, as filed on 08/13/2026, have been fully considered but not found persuasive. Applicant argued that Hoshimoto provides no sufficient reason to modify compound 5 to compound of claim 4 as Hoshimoto’s other compounds do not provide good yield. Applicant argued that modification of compound 5 of the cited prior art would change into asymmetric compound and the cited prior art provides no SAR. Applicant argued that based on Hoshimoto and In re Petering, it is not obvious to try. Applicant argued that claims 5-8 are further removed from Hoshimoto. Applicant argued over catalytic process chemistry of Hoshimoto. Applicant argued over unpredictability based on ring C. This is not found persuasive and the instant claims stand rejected. This is because (1) if Hoshimoto has provided elected species of the instant claims, the rejection would have been anticipation; (2) Hoshimoto discloses triarylborane compounds, such as Compound 5, closely similar to the elected species with same substitutions on rings X and X’ and halogen substitution at both positions 2 and 6 of ring Y with a difference that both halogens on ring Y of the cited prior art are Cl vs elected species one halogen is F and the other halogen is Br. The cited prior art further teaches superior catalytic activity of compound 5 in reductive alkylation of amine. Since the cited prior art teaches halogen, specifically Cl, at both 2 and 6 positions of ring Y and halogen genus contains a small number of members, it would have been prima facie obvious to a person of ordinary skill in the art with a reasonable expectation of success that Cl at position 2 and 6 may be replaced with other halogen, such as F, Br and I. Further a person of ordinary skill in the art would have been motivated to try other halogens at these positions based on prior art teaching of superior catalytic activity of the compound. Since the cited prior art teaches halogen, specifically Cl, at both 2 and 6 positions of ring Y and halogen genus contains a small number of members that, when considered in light of the totality of the circumstances, “one skilled in [the] art would... envisage each member” of the genus. In re Petering, 301 F.2d 676, 681, 133 USPQ 275, 280 (CCPA 1962); (3) Since Hoshimoto’s other compounds didn’t provide good yield, as agreed by the applicant, this in fact gives motivation to start with compound 5, which gave good yield; (3) Substituting one halogen with another might change symmetry, however, the cited prior art doesn’t says that a small change in symmetry may affect the activity. Since the cited prior art teaches halogen, specifically Cl, at both 2 and 6 positions of ring Y and halogen genus contains a small number of members that, when considered in light of the totality of the circumstances, “one skilled in [the] art would... envisage each member” of the genus. In re Petering, 301 F.2d 676, 681, 133 USPQ 275, 280 (CCPA 1962); (4) If the cited prior art would have provided entire SAR, the rejection would have been anticipation; (5) applicant only argued but provided no experimental evidence on changing halogen with another halogen and effect on yield and SAR; (6) Claims 5-8 includes elected species and is not removed from claim 4; (7) the instant claims are drawn to a compound and not to a catalytic process, thus, applicant is arguing over a limitation not recited in the instant claims; (8) the instant claims are not reciting only ring C, thus applicant’s argument over only ring C is not persuasive; (9) applicant is suggested to provide true comparative data that substitution of halogen with another halogen of compound 5 results unpredictable result. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion No Claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PANCHAM BAKSHI whose telephone number is (571)270-3463. The examiner can normally be reached M-Thu 7-4.30 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Milligan Adam can be reached at 571-2707674. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PANCHAM BAKSHI/Primary Examiner, Art Unit 1623
Read full office action

Prosecution Timeline

Jun 16, 2023
Application Filed
May 13, 2026
Non-Final Rejection mailed — §103, §112
Aug 13, 2026
Response Filed
Sep 17, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780850
PROCESS FOR SYNTHESIS OF ORGANOSILICON COMPOUNDS FROM HALOSILANES
3y 9m to grant Granted Nov 03, 2026
Patent 12768846
GOLD NONOCLUSTERS, DOPAMINE BIOSENSORS INCLUDING THEM, AND METHODS FOR DIAGNOSING NEUROLOGICAL DISEASES USING THE SAME
3y 6m to grant Granted Oct 20, 2026
Patent 12767628
METHOD FOR PREPARING ACRYLIC ACID
3y 4m to grant Granted Oct 20, 2026
Patent 12751963
Small Molecule Inhibitors of Viral Replication
4y 11m to grant Granted Oct 06, 2026
Patent 12751908
PEPTIDE COMPOSITION AND METHOD FOR PRODUCING SAME
4y 0m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
99%
With Interview (+30.1%)
2y 3m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1176 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month